Engineering of CRISPR-Cas12b for human genome editing

Jonathan Strecker(Broad Institute), Sara R. Jones(Broad Institute), Balwina Koopal(Broad Institute), Jonathan L. Schmid‐Burgk(Broad Institute), Bernd Zetsche(Broad Institute), Linyi Gao(Broad Institute), Kira S. Makarova(National Institutes of Health), Eugene V. Koonin(National Institutes of Health), Feng Zhang(Broad Institute)
Nature Communications
January 9, 2019
Cited by 357Open Access
Full Text

Abstract

The type-V CRISPR effector Cas12b (formerly known as C2c1) has been challenging to develop for genome editing in human cells, at least in part due to the high temperature requirement of the characterized family members. Here we explore the diversity of the Cas12b family and identify a promising candidate for human gene editing from Bacillus hisashii, BhCas12b. However, at 37 °C, wild-type BhCas12b preferentially nicks the non-target DNA strand instead of forming a double strand break, leading to lower editing efficiency. Using a combination of approaches, we identify gain-of-function mutations for BhCas12b that overcome this limitation. Mutant BhCas12b facilitates robust genome editing in human cell lines and ex vivo in primary human T cells, and exhibits greater specificity compared to S. pyogenes Cas9. This work establishes a third RNA-guided nuclease platform, in addition to Cas9 and Cpf1/Cas12a, for genome editing in human cells.


Related Papers

No related papers found

Powered by citation graph analysis